BACKGROUND: Severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome has been long suspected of having a genetic origin. Recently, mutations in SCN1A and GABRG2 have been described in SMEI patients. The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations. In order to further investigate the role of SCN1A and GABRG2 in the pathogenesis of SMEI we have screened for mutations three families with at least two members affected by Dravet syndrome. METHODS: Clinical criteria followed the international classification of epileptic syndromes. Mutational screening of SCN1A and GABRG2 genes was performed by denaturing high performance liquid chromatography (DHPLC) and direct sequencing of DNA fragments showing a variant chromatogram. RESULTS: Thirty-eight fragments spanning 26 exons of SCN1A and nine exons of GABRG2 were analysed in three probands. Five variant chromatograms were identified; four corresponded to known polymorphisms, one to a novel dinucleotide insertion on exon 26 of SCN1A. The mutation leads to a frameshift and a premature stop codon at amino acid 1 779 of the protein. The mutation was present in the affected sibling and was inherited from the mother who had experienced a single febrile seizure in childhood. CONCLUSIONS: Among three families analysed, a single family was mutant for SCN1A. Our study suggests that the syndrome is genetically heterogeneous. The variable expressivity we observed for the c5240insAA mutation suggests that other factors are needed for the development of the full SMEI phenotype.
BACKGROUND: Severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome has been long suspected of having a genetic origin. Recently, mutations in SCN1A and GABRG2 have been described in SMEI patients. The sporadic nature of the SMEI syndrome and the occurrence of SCN1A and GABRG2 mutations in a mild familial phenotype, termed generalized epilepsy with febrile seizure plus complicates genotype-phenotype correlations. In order to further investigate the role of SCN1A and GABRG2 in the pathogenesis of SMEI we have screened for mutations three families with at least two members affected by Dravet syndrome. METHODS: Clinical criteria followed the international classification of epileptic syndromes. Mutational screening of SCN1A and GABRG2 genes was performed by denaturing high performance liquid chromatography (DHPLC) and direct sequencing of DNA fragments showing a variant chromatogram. RESULTS: Thirty-eight fragments spanning 26 exons of SCN1A and nine exons of GABRG2 were analysed in three probands. Five variant chromatograms were identified; four corresponded to known polymorphisms, one to a novel dinucleotide insertion on exon 26 of SCN1A. The mutation leads to a frameshift and a premature stop codon at amino acid 1 779 of the protein. The mutation was present in the affected sibling and was inherited from the mother who had experienced a single febrile seizure in childhood. CONCLUSIONS: Among three families analysed, a single family was mutant for SCN1A. Our study suggests that the syndrome is genetically heterogeneous. The variable expressivity we observed for the c5240insAA mutation suggests that other factors are needed for the development of the full SMEI phenotype.
Authors: Linda Volkers; Kristopher M Kahlig; Nienke E Verbeek; Joost H G Das; Marjan J A van Kempen; Hans Stroink; Paul Augustijn; Onno van Nieuwenhuizen; Dick Lindhout; Alfred L George; Bobby P C Koeleman; Martin B Rook Journal: Eur J Neurosci Date: 2011-08-22 Impact factor: 3.386
Authors: J P Johnson; Thilo Focken; Kuldip Khakh; Parisa Karimi Tari; Celine Dube; Samuel J Goodchild; Jean-Christophe Andrez; Girish Bankar; David Bogucki; Kristen Burford; Elaine Chang; Sultan Chowdhury; Richard Dean; Gina de Boer; Shannon Decker; Christoph Dehnhardt; Mandy Feng; Wei Gong; Michael Grimwood; Abid Hasan; Angela Hussainkhel; Qi Jia; Stephanie Lee; Jenny Li; Sophia Lin; Andrea Lindgren; Verner Lofstrand; Janette Mezeyova; Rostam Namdari; Karen Nelkenbrecher; Noah Gregory Shuart; Luis Sojo; Shaoyi Sun; Matthew Taron; Matthew Waldbrook; Diana Weeratunge; Steven Wesolowski; Aaron Williams; Michael Wilson; Zhiwei Xie; Rhena Yoo; Clint Young; Alla Zenova; Wei Zhang; Alison J Cutts; Robin P Sherrington; Simon N Pimstone; Raymond Winquist; Charles J Cohen; James R Empfield Journal: Elife Date: 2022-03-02 Impact factor: 8.140
Authors: Pasquale Parisi; Alberto Spalice; Francesco Nicita; Laura Papetti; Fabiana Ursitti; Alberto Verrotti; Paola Iannetti; Maria Pia Villa Journal: Curr Neuropharmacol Date: 2010-12 Impact factor: 7.363
Authors: Gustavo A Patino; Lieve R F Claes; Luis F Lopez-Santiago; Emily A Slat; Raja S R Dondeti; Chunling Chen; Heather A O'Malley; Charles B B Gray; Haruko Miyazaki; Nobuyuki Nukina; Fumitaka Oyama; Peter De Jonghe; Lori L Isom Journal: J Neurosci Date: 2009-08-26 Impact factor: 6.167
Authors: Nanda A Singh; Chris Pappas; E Jill Dahle; Lieve R F Claes; Timothy H Pruess; Peter De Jonghe; Joel Thompson; Missy Dixon; Christina Gurnett; Andy Peiffer; H Steve White; Francis Filloux; Mark F Leppert Journal: PLoS Genet Date: 2009-09-18 Impact factor: 5.917
Authors: Linda Volkers; Kristopher M Kahlig; Joost H G Das; Marjan J A van Kempen; Dick Lindhout; Bobby P C Koeleman; Martin B Rook Journal: J Gen Physiol Date: 2013-12 Impact factor: 4.086